Clinigen Group (CLIN)

 

CLIN Share PerformanceMore

52 week high860.0 17/02/17
52 week low492.8 16/06/16
52 week change 229.0 (36.76%)
4 week volume4,809,024 24/01/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Broker Forecast - Stifel issues a broker note on Clinigen Group

Stifel today reaffirms its buy investment rating on Clinigen Group (LON:CLIN) and raised its price target to 900p (from 8...

Broker Forecast - N+1 Singer issues a broker note on Clinigen Group

N+1 Singer today reaffirms its buy investment rating on Clinigen Group (LON:CLIN) and raised its price target to 895p (fr...

Clinigen gross profit up 34%

Clinigen Group's gross profits rose by 34% in the six months to the end of December. This was driven by a combination of...

HY trading update

RNS Number: 0139V Clinigen Group plc 25 January 2017 25 January 2017 HY trading update: strong H1 performance with gross profit up 34% Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, today provides a trading update for the six months ended 31 December 2016. Highlights Gross profit* up 34% driven b...

Clinigen initiates programme for TESARO inhibitor

Clinigen Group's Idis Managed Access division has partnered with TESARO Inc to launch a managed access programme f...

Clinigen initiates program for TESARO's niraparib

RNS Number: 3742U Clinigen Group plc 17 January 2017 17 January 2017 Clinigen initiates U.S. Managed Access program for TESARO's niraparib for patients with ovarian cancer Clinigen Group plc's (AIM: CLIN, 'Clinigen') Idis Managed Access (MA) division has partnered with TESARO Inc. ( NASDAQ: TSRO), to launch a Managed Access program (also known as a...

Change of Joint Broker

RNS Number: 8046T Clinigen Group plc 13 January 2017 13 January 2017 Change of Joint Broker Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services group, announces that it has appointed RBC Capital Markets to act as its Joint Broker with immediate effect. Numis Securities Limited continues to act as Nominated Adviser...

Clinigen and Cumberland enter agreement for Totect

Clinigen Group and Cumberland Pharmaceuticals have announced an exclusive agreement to commercialise the oncology...

Fundamental DataMore

P/E ratio71.597
EPS11.9
Dividend yield0.469 %

Equity Research (CLIN)

edison investment research
Clinigen Group Plc
01/03/2016
Edison Investment Research is terminating coverage on Clinigen Group (CLIN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be...
edison investment research
Clinigen Group Plc
25/01/2016
Clinigen’s H116 trading statement suggests its business is performing to plan, taking into account some revenue deferrals to H2. The integration of Idis and Link, which we expect to boost its...
edison investment research
Clinigen Group Plc
13/10/2015
Clinigen’s FY15 results demonstrated strong underlying fundamentals, with earnings and net debt better than our forecasts. The integration of Idis and the purchase of Link further its strategy as the...

Latest discussion posts More

  • Re: Trading Statement

    No... Trading statement on the 25th. Ambiorix.
    19-Jan-2017
    Ambiorix1
  • Trading Statement

    Obviously not 19th.January ???
    19-Jan-2017
    rig mover
  • A bit of hidden good news in anticipation of the up and coming half year trading update on 19th January
    3-Jan-2017
    bushwhacker

Users' HoldingsMore

Users who hold Clinigen Group also hold..
GLAXOSMITHKLINE20%
BP19%
RDS 'B'18%
LLOYDS GRP.17%
NATIONAL GRID16%

Codes & Symbols

ISINGB00B89J2419
SymbolsCLIN, LSE:CLIN, CLIN.L, CLIN:LN, LON:CLIN, XLON:CLIN